Stocksigma LogoStocksigma Logo

Aurobindo Pharma Delivers Strong Q2FY27 Results with Record Revenue and Margins

Aurobindo Pharma reported its highest-ever quarterly revenue of ₹10,263 Cr in Q2FY27, up 23.9% YoY and 12.2% QoQ, driven by solid formulation growth across

Aurobindo Pharma Delivers Strong Q2FY27 Results with Record Revenue and Margins

Aurobindo Pharma Ltd · Investor Presentation · 05 Nov 2026, 1:35 am

Aurobindo Pharma Delivers Strong Q2FY27 Results with Record Revenue and Margins Aurobindo Pharma reported its highest-ever quarterly revenue of ₹10,263 Cr in Q2FY27, up 23.9% YoY and 12.2% QoQ, driven by solid formulation growth across the US (+25.2% YoY) and Europe (+27.5% YoY). EBITDA reached a record ₹2,156 Cr (+28.5% YoY) with margins expanding 75 bps YoY to 21.0%, while PAT rose 32.5% YoY to ₹1,124 Cr. The company completed the Lannett acquisition, generated US$ 146mn in net cash flow, and maintained a net cash position of ~US$ 189mn as of 30th Sep'26.

Original exchange filing (PDF)

More announcements from Aurobindo Pharma Ltd

All Aurobindo Pharma Ltd announcements